A first-in-class, first-in-human, phase I trial of CIGB-552, a synthetic peptide targeting COMMD1 to inhibit the oncogenic activity of NF-κB in patients with advanced solid tumors.

Autor: Vallespi MG; Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba., Mestre B; National Institute of Oncology and Radiobiology (INOR), Havana, Cuba., Marrero MA; National Coordinating Center for Clinical Trials (CENCEC), Havana, Cuba., Uranga R; National Coordinating Center for Clinical Trials (CENCEC), Havana, Cuba., Rey D; National Coordinating Center for Clinical Trials (CENCEC), Havana, Cuba., Lugiollo M; National Institute of Oncology and Radiobiology (INOR), Havana, Cuba., Betancourt M; National Institute of Oncology and Radiobiology (INOR), Havana, Cuba., Silva K; National Institute of Oncology and Radiobiology (INOR), Havana, Cuba., Corrales D; National Institute of Oncology and Radiobiology (INOR), Havana, Cuba., Lamadrid Y; National Institute of Oncology and Radiobiology (INOR), Havana, Cuba., Rodriguez Y; National Institute of Oncology and Radiobiology (INOR), Havana, Cuba., Maceo A; National Coordinating Center for Clinical Trials (CENCEC), Havana, Cuba., Chaviano PP; National Coordinating Center for Clinical Trials (CENCEC), Havana, Cuba., Lemos G; Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba., Cabrales A; Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba., Freyre FM; Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba., Santana H; Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba., Garay HE; Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba., Oliva B; Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba., Fernandez JR; Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba.

Publikováno v: International journal of cancer [Int J Cancer] 2021 Sep 15; Vol. 149 (6), pp. 1313-1321. Date of Electronic Publication: 2021 May 27.

Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients.

Autor: Mazorra Z; Department of Clinical Immunology, Clinical Direction, Center of Molecular ImmunologyHavana, Cuba., Lavastida A; Department of Clinical Immunology, Clinical Direction, Center of Molecular ImmunologyHavana, Cuba., Concha-Benavente F; Department of Immunology, University of Pittsburgh, PittsburghPA, United States., Valdés A; Department of Clinical Immunology, Clinical Direction, Center of Molecular ImmunologyHavana, Cuba., Srivastava RM; Department of Otolaryngology, University of Pittsburgh, PittsburghPA, United States., García-Bates TM; Department of Infectious Diseases and Microbiology, Graduate School of Public Health, University of Pittsburgh, PittsburghPA, United States., Hechavarría E; Department of Clinical Immunology, Clinical Direction, Center of Molecular ImmunologyHavana, Cuba., González Z; Department of Clinical Immunology, Clinical Direction, Center of Molecular ImmunologyHavana, Cuba., González A; Department of Clinical Immunology, Clinical Direction, Center of Molecular ImmunologyHavana, Cuba., Lugiollo M; National Institute of Oncology and RadiobiologyHavana, Cuba., Cuevas I; National Institute of Oncology and RadiobiologyHavana, Cuba., Frómeta C; National Institute of Oncology and RadiobiologyHavana, Cuba., Mestre BF; National Institute of Oncology and RadiobiologyHavana, Cuba., Barroso MC; Clinical Direction, Center of Molecular ImmunologyHavana, Cuba., Crombet T; Clinical Direction, Center of Molecular ImmunologyHavana, Cuba., Ferris RL; Department of Immunology, University of Pittsburgh, PittsburghPA, United States.; Department of Otolaryngology, University of Pittsburgh, PittsburghPA, United States.; Cancer Immunology Program, University of Pittsburgh Cancer Institute, PittsburghPA, United States.

Publikováno v: Frontiers in pharmacology [Front Pharmacol] 2017 Jun 19; Vol. 8, pp. 382. Date of Electronic Publication: 2017 Jun 19 (Print Publication: 2017).